Company: HURA
Filing Date: 2025-12-05
Form Type: 8-K
Source: 0001193125-25-309853
Chunk: 0

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-12-05
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

Amendment to Secured Promissory Note and Loan Agreement

As disclosed in a Current Report on Form 8-K filed by TuHURA Biosciences, Inc. (the “ Company”) on October 31, 2025, the Company previously entered into a Secured Promissory Note and Loan Agreement, dated October 27, 2025 (the “ Loan Agreement”), with the Matthew Nachtrab Revocable Trust dated 12/18/2014 (the “ Lender”). Pursuant to the terms of the Loan Agreement, the Lender agreed to make loans to the Company in an aggregate principal amount of up to $3.0 million (the “ Loans”) during a 30-day availability period beginning on the date of the Loan Agreement (the “ Availability Period”). The Lender advanced the first Loan to the Company in the amount of $1.5 million simultaneously with the execution of the Loan Agreement (the “ First Loan”).

On December 2, 2025, the Company and Lender entered into an amendment to the Loan Agreement (the “ Amendment”) pursuant to which (i) the Lender agreed to extend the Availability Period to December 5, 2025 and (ii) the Company and Lender agreed that warrants issuable to the Lender under the Loan Agreement would consist of a warrant to purchase 150,000 shares of Company common stock for each $1.5 million of funds borrowed under the Loan Agreement (including under the First Loan), prorated for borrowings less than $1.5 million. Except for the foregoing, the Amendment included no further changes to the original Loan Agreement.

Following the execution of the Amendment, on December 2, 2025, the Company borrowed an additional $1.5 million from the Lender under the Loan Agreement (the “ Second Loan”), which resulted in aggregate Loans of $3.0 million made to the Company under the Loan Agreement. On the same date, the Company issued to the Lender an additional warrant to purchase an aggregate of 234,783 shares of Company common stock at an exercise price of $1.81 per share (the closing price of the Company’s common stock on the Nasdaq Stock Market on the date of issuance), consisting of 84,783 shares as a result of the First Loan and 150,000 shares as a result of the Second Loan. Such warrant will expire two years from the issuance date thereof.